Huseynova IE¹*, Hasanov AQ¹, Mammadova FM¹ and Gafarov IA²

¹Department of Children's Diseases II, Azerbaijan Medical University, Azerbaijan, Baku
²Department of Medical Physics and Informatics, Azerbaijan, Baku

*Corresponding Author: Huseynova IE, Department of Children's Diseases II, Azerbaijan Medical University, Azerbaijan, Baku.

Received: August 17, 2023; Published: October 16, 2023

Abstract

The purpose of the study was to analyze and compare the clinical and laboratory results of COVID-19 disease in different pediatric age groups. Our research shows that children of all ages are vulnerable to COVID-19. For this purpose, 75 patients aged from 1 month to 17 years were included in the study. Patients were divided into three age groups: up to 1 year, 1-3 years, 4-17 years. The diagnosis of patients with COVID-19 was confirmed by a polymerase chain reaction (PCR) nasopharyngeal swab, and an X-ray examination of their lungs determined unilateral or bilateral pneumonia. Clinical manifestations of the disease in children were characterized by intoxication of varying severity. It is clear from the study that common symptoms across all age groups were fever and cough. Loss of smell and taste, muscle pain, and headache, characteristic of COVID-19, were recorded mainly in the 4-17 years. Lethargy, cyanosis, reduced reaction to the environment, and muscle hypotension were more often observed in children under 1 year of age. Laboratory examination revealed an increased level of anti-inflammatory cytokines (IL-1x, IL-6, IL-18), ferritin, fibrinogen, D-dimer in children. The biological mechanisms that determine age-related differences in the disease are still not fully understood, but the proposed hypotheses can be explained by age-related differences in the activity and maturity of the immune system of infants and adults.

 Keywords: COVID-19; Pediatric Age Groups; Clinical Features

References

1. Lee PJ., et al. “Are children less susceptible to COVID-19”. Journal of Microbiology, Immunology and Infection 3 (2020): 371-372.
2. Hong H., et al. “Clinical characteristics of novel disease 2019 (COVID-19) in newbons, infants and children”. Pediatric Neanatology 61 (2020): 131.
3. Petrov OI., et al. “Clinical and epidemiological features of the new coronavirus infection COVID-19 in children”. Modern Problems of Science and Education 3 (2022): 232-236.
4. Martins MM., et al. “Clinical and laboratory characteristics of children with SARS-CoV-2 infection in children and adolescents”. Revista Paulista de Pediatria 39 (2021): 2020231.
5. Dhochac NK., et al. “Pathophysiology of COVİD-19: Why children fare better than adults”. İndian Pediatrics 87 (2020): 537-546.
6. Luo H., et al. “Age differences in clinical features and outcomes in patients with COVID-19 Jiangus, China: a retrospective, multicentre cohort study”. BMJ 10 (2020): 39887.v
7. Ding Y., et al. “Clinical characteristics of children with COVID-19: a meta-analysis”. Frontiers in Pediatrics 8 (2020): 431.
8. Dong Y., et al. “Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China”. Journal of Emergency Medicine 4 (2020): 712-713.
9. Rankin DA., et al. “Epidemiologic trends children in the United State”. Current Opinion in Pediatrics 33 (2021): 114-121.
10. Karbuz A., et al. “Epidemiological, clinical and laboratory of with COVID-19 in Turkey”. Frontiers in Pediatrics 9 (2021): 631547.
11. Hoang A., et al. “COVID-19 in 7780 pediatric patients: a systematic review”. EClinical Medicine 24 (2020): 100433.
12. Vanetti C., et al. “The immunological profile of SARS-CoV-2 infection in children is linked to clinical severity and age”. International Journal of Molecular Sciences7 (2023): 67-79.
13. Mustafa NM and Selim L. “Characterisation of COVID-19 pandemic in pediatric age group: a systematic review and meta analysis /N.M. Mustafa, L. Selim”. Journal of Clinical Virology 128 (2020): 104339.
14. Akmayeva MA., et al. “Features of the new coronavirus infection in children of different ages”. Journal of Children's Infections2 (2021): 5-9.
15. Siddiqui M., et al. “Comparison of clinical features and laboratory findings of coronavirus disease 2019 and influenza A and B infection in children: a single-center study”. Clinical and Experimental Pediatrics7 (2021): 356-369.
16. Stopyra L., et al. “The age related course of COVID-19 in pediatric patents-1405 cases in a single centre”. Journal of Clinical Medicine24 (2022): 7347.
17. Kepenekli E., et al. “COVID-19 disease characteristics in different pediatric age groups”. Journal of Infection in Developing Countries 1 (2021): 16-24.
18. Siddiqui M., et al. “Comparison of clinical features and laboratory findings of coronavirus disease 2019 and influenza A and B infection in children: a single-center study”. Clinical and Experimental Pediatrics7 (2021): 356-369.
19. Huseynova İE., et al. “Clinical characteristics of with COVID-19 pneumonia”. İnternational Journal of Medical, Pharmacy and Drug Research3 (2023): 1-8.
20. Qiu C., et al. “Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study”. Otolaryngology–Head and Neck Surgery 163 (2020): 14-21.
21. Wenjie L., et al. “Early immune responses and factors with COVID-19: a single-center rettospective analysis”. BMJ Pediartiya1 (2021): 181.
22. Qian G., et al. “Reduced inflammatory respones to SARS-CoV-2 infection in children presenting to hospital with COVID-19 in China”. Clinical Medicine 34 (2021): 100831.
23. Sun D., et al. “Clinical feature of severe pediatric patients with coronavirus disese 2019 in Wuhan: a single centers observational study”. World Journal of Pediatrics3 (2020): 251-259.
24. Ulhaq ZS and Soraya GV. “İnterleukin 6 as a potential biomarker of COVID-19 progression”. Médecine et Maladies Infectieuses 4 (2020): 382-383.
25. Hala KŞ., et al. “Cytokine profiypfile in Egyptian children and adolescent with COVID-19 pneumonia: A multicenter study”. Pediatric and Pulmonology12 (2021): 3924-3933.
26. Curatola A., et al. “Cytokine response to SARS-CoV-2 infektion in children”. Viruses9 (2021): 1868.
27. Han H., et al. “Prominent changes in blood coagulation of patients with Sars-CoV-2 infection”. Journal of Clinical Chemistry and Laboratory Medicine 7 (2020): 1116-1120.
28. Kausal K., et al. “Serum ferritin as a predictive biomarker in COVID-19. A systematic review, metanalysis and meta regression analysis”. Journal of Critical Care 67 (2022): 171-181.
29. Zou Y., et al. “Analysis of coagulation parameters in patients with COVİD-19 in Shanghai, China”. Bioscience in Trends4 (2020): 285-289.
30. Hasanov AG and Huseynova İY. “İndicators of vitamin D in case of COVID-19 in children”. Modern Pediatris. Ukraine 7.119 (2022): 34-39.
31. Yılmaz K and Şen V. “İs vitamin D deficiency a risk factor for COVID-19 in children?”. Pediatric Pulmonology12 (2020): 3595-3601.
32. Akoğlu HA., et al. “Evaluation of childhood COVID-19 cases: a retrospective analysis”. Journal of Pediatric Infectious Diseases 16 (2021): 91-98.
33. Telcian AG., et al. “Vitamin D increases the antiviral activity of bronchial epithelial cell in vitro”. Antiviral Research 137 (2017): 93-101.
34. Rhodes JM., et al. “Perspective: Vitamin D deficiency and COVID-19 severity-plausibly linked by latitude, ethnicity, impact on cytokines, ACE 2 and thrombosis”. İnternal Medicine1 (2020): 97-115.

Citation

Citation: Huseynova IE., et al. “Clinical and Laboratory Features of COVID-19 in Different Pediatric Age Groups”.Acta Scientific Medical Sciences 7.11 (2023): 63-73.

Copyright

Copyright: © 2023 Huseynova IE., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.